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It has long been hypothesized that elastic modulus governs the
biodistribution and circulation times of particles and cells in blood;
however, this notion has never been rigorously tested. We synthe-
sized hydrogel microparticles with tunable elasticity in the physio-
logical range, which resemble red blood cells in size and shape,
and tested their behavior in vivo. Decreasing the modulus of these
particles altered their biodistribution properties, allowing them to
bypass several organs, such as the lung, that entrapped their more
rigid counterparts, resulting in increasingly longer circulation times
well past those of conventional microparticles. An 8-fold decrease
in hydrogel modulus correlated to a greater than 30-fold increase in
the elimination phase half-life for these particles. These results de-
monstrate a critical design parameter for hydrogel microparticles.
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The ability of mammalian cells to contract or stretch stronglyinfluences their motility and biodistribution (1). The extraor-
dinary flexibility of mammalian RBCs enables them to deform
many thousands of times during their long lives in the circulation
with up to 100% strain (2) as they pass through restrictions in the
vasculature that is smaller than their diameter. During their 120-d
lifetime, RBCs experience chemical changes to their membrane
structure, rendering them less flexible, and leading to their
removal from the circulation via splenic filtration (3). Beyond
RBCs, cancer cells, especially metastatic cancer cells, are elasti-
cally softer than healthy cells, a characteristic that is believed to
be integral to their ability to spread to new locations (1, 4).
Although much attention has been directed toward the enhance-
ment of the circulation time of particles, including alterations of
particle size (5, 6), shape (7–9), and surface characteristics (10),
the role played by deformability in the in vivo circulation profile
of particles has not been well explored.
Though particle size has long been considered dominant in
determining in vivo behaviors such as circulation time and biodis-
tribution profile, it stands to reason that physical filtration
barriers in the body could be navigated by larger, but more de-
formable particles (11, 12). Deformable particles that resembled
RBCs in size and shape have been shown to deform in restricted
channels (13) or capillaries (14) that were smaller than the
particle diameter, though the modulus of these particles was not
characterized (13) or was poorly matched to RBCs (14) and was
restricted to in vitro testing in both cases. In a simulation of renal
filtration of soft particles, microgels translocated through pores
that were 1∕10th of the particle diameter under physiologically
relevant pressures (15). Filamentous worm-like micelles were
found to have increased circulation times with respect to their
spherical counterparts, though this effect was attributed to the
size and shape of these particles as well as the deformability (8).
Inspired by nature’s example of long-circulating microparticles,
we sought to mimic the size and shape of RBCs while varying
the modulus across a physiologically relevant range to probe the
physical barriers encountered in vivo by soft microparticles. Here
we show that increasing the deformability of RBC-sized particles
increased their circulation times beyond that of conventional
microparticles and significantly altered their biodistributions.
We found that, as a consequence of their low modulus, these dis-
coid microparticles bypassed several in vivo filtration mechan-
isms, illustrated by animal survival and dramatic increases in
elimination half-lives of particles with decreasing modulus. Such
deformable and long-circulating particles may find utility in the
fields of drug delivery and medical imaging, where long-circula-
tion times and varied biodistributions are often desirable charac-
teristics (6, 16, 17). Further, we expect these results will stand as
an introduction for particle deformability as a vital design para-
meter that can affect the behavior of particles on both the micro-
and nanoscales.
Results and Discussion
Fabrication of Red Blood Cell Mimics (RBCMs). The particle replica-
tion in nonwetting templates (PRINT®) technique that has
been developed in our laboratory allows for the fabrication of
nonspherical, shape-specific particles through use of elastomeric
fluoropolymer molds (18, 19). Using PRINT, we fabricated par-
ticles with similar size, shape, and deformability characteristics as
RBCs (Fig. 1). In this study we chose to model the 6-μm diameter
mouse RBC (20) and observe the in vivo behavior of the RBCMs.
Although the distinctive biconcave discoidal shape of mature
RBCs is generally conserved throughout the animal kingdom,
mouse RBCs (6-μm diameter) are slightly smaller than their
human counterparts (8-μm diameter) (20). Many hydrogels exhi-
bit excellent biocompatibility (21), with their swelling and
deformability controllable by varying the amount of cross-linking
in the gel (22). We used hydrogels composed primarily of 2-hy-
droxyethyl acrylate (HEA) that were lightly (1–10%, by weight)
cross-linked with poly(ethylene glycol) diacrylate (PEGDA,
MW ¼ 4;000 g∕mol) with a photoinitiator (1-hydroxycyclohexyl
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phenyl ketone), and polymerizable fluorescent dyes (1%) to
facilitate imaging. To mimic the negatively charged RBC mem-
brane, we added 2-carboxyethyl acrylate (10%). See Table S1
for further details on hydrogel composition.
To evaluate the suitability of this hydrogel for RBCM particles,
we hydrated macroscopic coupons of hydrogels with varying per-
centage of PEGDA cross-linker at neutral pH and tested their
mechanical properties with an Instron 5556 Universal Testing
Machine (Instron) with a strain rate of 5 mm∕min. For bulk mod-
ulus studies we used fluorescein-o-acrylate as the polymerized
dye, and to improve depth of tissue penetration and avoid tissue
autofluorescence, a near-IR dye (Dylight680maleimide) was used
for in vivo applications. By lowering the amount of cross-linker
from 10% to 1%, we tuned the modulus of the resultant hydrated
polymer from 63.9 to 7.8 kPa, respectively (Table 1), overlapping
the range of the reported modulus for RBCs (26 7 kPa) (23).
Because of the swelling observed in the bulk hydrogel samples,
we designed scaled-down master templates and molds for this
study. The scaled-down features of the molds, with diameters
of 2 or 3 μm, allowed the RBCMs to swell to the desired dimen-
sions upon hydration, yielding discs that were 5.2–5.9 μm in
diameter and 1.22–1.54 μm tall, with the feature size and final
RBCM dimensions dependent upon the percent of cross-linker
and the mold used. Filling the molds resulted in a meniscus,
leaving the particles thinner in the middle and thicker at the
edges (Fig. 1). This effect, which is not uncommon for the PRINT
method (9), yielded RBCMs that were reminiscent of the bicon-
cave shape of RBCs.
To assess the biocompatibility of the RBCMs, we performed
in vitro cytotoxicity assays on human umbilical vein endothelial
cell (HUVEC) (endothelial) cells. We dosed cells with varied con-
centrations of RBCMs (1.5–200 μg∕mL) and incubated for 72 h
(Fig. S1) before performing both MTS [(3-(4,5-dimethylthiazol-2-
yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium)]
and ATP-luciferase assays to assess cell life. Particles were well
tolerated at all dosages tested by both assays. To examine the
interaction of RBCMs with endothelial cells, we performed a flow
cytometry-based cell uptake experiment (24). RBCMs were
dosed to HUVEC cells at a concentration of 15 μg∕mL and in-
cubated for 15 min, 1, 2, 4, and 24 h, and then evaluated to de-
termine the percentage of cells that had internalized the RBCM
particles. Interaction between the RBCMs and cells was minimal,
with less than 10% of cells having internalized particles after 24 h
of incubation time (Fig. S2).
Microfluidic Examination of Particle Deformability. To demonstrate
the ability of RBCMs to deform in flow conditions such as they
might experience in traversing the microvasculature, we utilized a
microfluidic device with constricted pores (Fig. 2). Microfluidic
models of vascular constriction have been explored to evaluate
the behavior of natural and diseased RBCs (25) and synthetic
mimics of RBCs (13). We designed a 3-μm tall channel with pores
that were 3 μm wide and 50 μm long and repeated many times
over the length of the device. The height of the channels was
too short for the RBCMs to orient vertically to pass through the
restrictions, forcing the particles to deform in order to traverse
the pores. The device design (Fig. 2A) included over 100 repeti-
tions of 3-μm restricted pores over the length of the channel, as
well as an unrestricted 15-μm path on each side of the restrictions,
running the length of the channel. This architecture tested the
ability of the particles to deform repeatedly while providing an
unobstructed path for fluid flow to maintain reasonably low pres-
sures through the constricted pathways. Although the smallest
capillaries in the body have diameters of around 5 μm, RBCs rou-
tinely deform to traverse splenic sinusoids that are much smaller
(26). When dilute solutions of RBCMs were flowed through the
device at a constant flow rate (0.06 mL∕min), the lower modulus
RBCMs (1 and 2% cross-linked) navigated these pores, whereas
more rigid RBCMs rapidly clogged them (Fig. 2). A movie of 1%
cross-linked RBCMs traversing these pores can be seen in SI Text
(Movie S1). In flow, the 1% cross-linked RBCMs stretched in the
3-μm wide channels, increasing in length 239% 26% (n ¼ 15)
while flowing through the restricted channels, followed by a re-
laxation back to their original discoid shape in the absence of
flow. This behavior is similar to that of natural RBCs, which de-
form under flow conditions and only fully resume their character-
istic discoid shape once flow is halted (27). Although RBCMs
have similar size, shape, and deformability to RBCs, they differ
Fig. 1. RBCM particles. (A) A graphical depiction of the
PRINT process used to fabricate RBCMs. Briefly (Top to
Bottom), an elastomeric fluoropolymer mold (green) with
disc-shaped wells was covered by an aliquot of the prepo-
lymer mixture (red). The mold was passed through a pres-
sured nip (black) covered by a high-energy sheet (gray),
wicking away excess liquid from the mold surface while
filling the wells of the mold. The filled mold was cured
photochemically, yielding cross-linked hydrogel particles,
which were harvested from the mold by freezing onto a
thin film of 1% poly(vinyl alcohol) in water (blue) and
peeling away the mold. Melting of this layer resulted in
a suspension of hydrogel particles. (B–E) Fluorescent images
of hydrated RBCMs with varying percent cross-linker;
(B) 10% cross-linked, (C) 5% cross-linked, (D) 2% cross-
linked, and (E) 1% cross-linked. Scale bars are 20 μm.
Table 1. Modulus values and compartmental analysis of RBCM particles from intravital microscopy experiments
% Cross-linker Modulus of bulk material, kPa Distribution half-life, h Elimination half-life, h AUC, fluoresence* h Average R2
10% 63.9 ± 15.7 0.038 ± 0.0012 2.88 ± 0.92 0.65 ± 0.14 0.8966
5% 39.6 ± 10.4 0.066 ± 0.036 5.12 ± 2.17 0.76 ± 0.57 0.9029
2% 16.9 ± 1.7 0.15 ± 0.025 7.12 ± 0.82 1.35 ± 0.26 0.9468
1% 7.8 ± 1.0 0.35 ± 0.13 93.29 ± 31.09 15.44 ± 15.63 0.9330
*Ranges given represent one standard deviation. Values were derived from scans of three mice.
























in fundamental structure: RBCs are fluid-filled sacs contained by
a complex membrane that has extreme flexibility originating from
the membrane structure (28, 29), whereas the RBCMs are unin-
terrupted hydrogel discs. These two disparate structures should
have different behaviors and mechanisms of deformation in con-
stricted flow (13) though further studies are needed to elucidate
these details for the RBCMs.
Compartmental Analysis of RBCM Circulation Profile After Intravenous
Administration.We used an intravital imaging method to examine
the behavior of RBCMs when intravenously injected into mice.
For intravital approaches, the microcirculation is directly ob-
served with high spatial and temporal resolution, often through
the use of surgical techniques to expose tissues of interest (30,
31). In our approach, we observed the peripheral vasculature
through the skin of an anesthetized mouse’s ear. We directly ob-
served the RBCMs via the near-IR fluorescence of the particles
by imaging every 2 s for 2 h as the particles traversed this portion
of the vasculature (see Movies S2 and S3). Elimination curves
were generated by tracking the change in fluorescent signal from
the particles over time (Fig. 3), normalizing each scan to the max-
imum intensity slice and plotting decay as a function of this max-
imum intensity.
Several pharmacokinetic models were investigated using a
standard pharmacokinetic modeling program [WinNonlin (ver-
sion 5.2.1; Pharsight Corp.)] to describe the plasma concentration
versus time profiles to determine the best model. One- and two-
compartment models with elimination from the central compart-
ment, from the software’s library, were investigated, as was a
two-compartment model with elimination from both the central
and peripheral compartments, which was built by our group. The
evaluation of the goodness of fit was based on the Akaike infor-
mation criterion, the variability of the parameter estimates, and
the absence of a significant correlation between independent
model parameters (<0.95). The two-compartment model with
one elimination step from the central compartment provided
the best fit for all of the datasets examined.
To evaluate the kinetics of RBCM clearance, we used this
two-compartment pharmacokinetic model, characterized by a
biexponential decrease in particle concentration over time (32),
with parameters fit by nonlinear regression analysis (33). This
model describes an initial (distribution) phase where the particles
Fig. 2. Microfluidic evaluation of RBCM deformability.
(A) A schematic of the microfluidic devices, with flow driven
by a syringe pump. (B) An image sequence showing a 1%
cross-linked RBCM (6.0-μm diameter) deforming to pass
through a 3 × 3.5 μm channel (25 ms between frames).
(C) Ten percent cross-linked RBCMs stuck in the entrance
of the 3-μm pores in a microfluidic device. Scale bars are
30 μm.
Fig. 3. Intravital microscopy data and compartmen-
tal analysis. (A) Vasculature highlighted with rhoda-
mine B labeled dextran prior to injection of RBCMs.
(B) Dylight 680 labeled 1% cross-linked RBCMs flow-
ing through this stretch of vasculature 20 min after
dosing, with ROI outlined in yellow. (C) Colored over-
lay of A and B, with dextran in blue and particles
shown in red. Scale bars are 100 μm. (D) Two-com-
partment model schematic and governing equations
used to fit the data. (E) Decrease in fluorescent signal
in the ROI for the 2-h scan in this mouse. The semilog
plot shows calculated fit for the two-compartment
pharmacokinetic models.
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distribute from the plasma into various tissues, followed by a late
(elimination) phase that describes the ultimate clearance of par-
ticles from the plasma (Fig. 3). For small molecules and nanopar-
ticles the distribution is attributed to extravasation into tissue;
because of their size, the distribution of RBCMs may be due
to physical entrapment in constricted capillaries or tissues with
low blood flow rather than by an extravasation process. Although
we observed the RBCMs only for the initial 2 h in vivo, the un-
certainty associated with the mathematical fitting was minimized
due to the large number of data points used to fit each curve (over
350). Calculated distribution and elimination half-lives (t1∕2ðαÞ
and t1∕2ðβÞ, respectively) trended to longer times with decreased
modulus (Table 1). Although the least flexible RBCMs were
cleared quite rapidly, circulation times increased with increasing
particle elasticity, with the most deformable RBCMs eliminated
over 30 times more slowly than their most rigid counterparts
(t1∕2ðβÞ ¼ 3.9 d).
Intravital microscopy provided a method for direct observation
of RBCM particles in the peripheral vasculature of mice and
allowed us to make a close and thorough examination of the
initial clearance profiles of these particles. Our analysis provided
curves with approximately 350 data points illustrating the elimi-
nation of these particles from the circulation over each 2-h scan.
Nonlinear regression analysis yielded excellent fits, with the large
number of data points adding a measure of certainty to the shape
defined by these elimination curves. With a method of directly
observing the particles, we expect that our detection limits should
be quite low as we are able to discern individual particles in the
scans. However, this method was not without limitations. Direct
correlation of the intensity of the fluorescent signal of the parti-
cles to a particle concentration was difficult due to several factors,
including variabilities in the depth, volume, and flow rates in
observed portions of vasculature and the relatively fast movement
of particles relative to the scanning speed of the microscope.
Lacking the correlation to particle concentration, we were unable
to perform a full pharmacokinetic analysis on the RBCMs exam-
ined, though much was learned through an analysis of the shape
of these curves.
To verify the long-circulating behavior of 1% cross-linked
RBCMs, we tracked particle concentration in blood at time
points out to 5 d postinjection via a more traditional blood-draw
method. We examined three mice per time point, including 2, 8,
24, 72, and 120 h postinjection. At each time point examined, we
sacrificed the mice, collected blood via cardiac puncture, and
measured the fluorescent signal from the particles in the whole
blood, which was correlated to concentration through the genera-
tion of a standard curve (see SI Text). Pharmacokinetic analysis of
these data by the two-compartment model discussed above was in
good agreement with the data obtained from the intravital tech-
nique; both techniques showed a fairly rapid distribution of the
majority of the dose to various tissues, with 10–15% remaining in
the blood after 2 h, resulting in an elimination half-life of 3.6 d,
with 5% of the injected dose remaining in the blood after 5 d
(Table 2).
Biodistribution of RBCM Particles After Intravenous Injection. To ex-
amine the biodistribution of RBCMs with changing deformabil-
ity, we sacrificed the mice 2 h postinjection and harvested tissue
and blood samples for further analysis. Tissue samples were
not perfused prior to analysis. Five and 10% cross-linked RBCMs
distributed primarily into the capillary beds in the lungs (Fig. 4).
This behavior is typical for intravenously injected micro-particles,
with the bulk of the dose most likely sequestered immediately
postinjection as this is the first downstream tissue with microvas-
culature. These stiffer RBCMs were poorly tolerated, with signif-
icant distress requiring sacrifice of some mice prior to scan
completion; presumably due to the stiff particles contributing
to pulmonary embolism. More flexible RBCMs (1 and 2% cross-
linker) were very well tolerated, presumably due to the avoidance
of filtration in the lungs. Mice that were sacrificed early were not
included in any datasets presented here, as the time postinjection
was incongruent with the bulk of the data analyzed. The most
deformable RBCMs (1% cross-linked) were primarily seques-
tered in the spleen (67% recovered fluorescence∕g), having lar-
gely avoided filtration in the lungs. Lung filtration was largely
avoided by particles with 2% or less cross-linker (≤16.9 kPa, bulk
material), suggesting that the modulus of these materials may in-
dicate a threshold value for avoidance of filtration by the lungs.
Uptake in the kidneys was significant for all but the 1% cross-
linked RBCMs, though further studies will be required to eluci-
date the mechanism of this clearance.
Distribution of 1% cross-linked RBCMs in liver, lung, spleen,
kidneys, and blood was tracked for 2, 8, 24, 72, and 120 h post-
injection (Figs. S4 and S5). Saturation of tissues occurred at
different times, indicating a redistribution of particles after some
initial distribution at the time of dosing. Although splenic accu-
mulation peaked at 24 h, signal in the lungs decreased over the
time course of the experiment; suggesting a delayed release of the
physically entrapped particles back into the circulation.
With approximately 5% of the cardiac output flowing through
the spleen (3) and the total blood volume of the mouse circulating
7–8 times per minute (34), the whole blood volume was passed
through the mouse spleen some 42–48 times over the course of
our 2-h scans. The continued persistence of 1% cross-linked
RBCMs in the circulation after this time suggests that splenic
accumulation may be due in part to long residence time rather
than permanent filtration, as is the case for RBCs, where filtra-
tion occurs first as an effect of slow blood flow through the
macrophage containing red pulp, followed by physical filtration
when passing through the sinusoids or transmural apertures (3).
Further studies will be required to illuminate the capability
of these particles to carry and deliver therapeutic payloads;
however, extremely low modulus RBCMs could have therapeutic
applications for splenic disorders due to their preferential accu-
mulation in this tissue and the have potential for drug delivery
applications due to their long-circulation times and low accumu-
lation in the liver. Drug dosing can be limited by toxicity to a
clearance organ such as the liver (35, 36). The apparent splenic
clearance of RBCMs affords the possibility of different dosing
restrictions if these particles were to be used as drug carriers be-
cause of the low concentrations found in the liver, as well as the
possibility for direct treatment or imaging of the spleen. The most
deformable of the RBCMs tested here successfully navigated re-
gions of constricted blood flow, resulting in extended circulation
times and illuminating a critical design parameter for micropar-
ticles. Further experimentation with extremely deformable mate-
rials on different size scales—from tens of nanometers to the
6-μm diameter particles used in this study, should cast light on
the role played by deformability in enhancing the circulation
times of biologically relevant particles.
Materials and Methods
Materials. Commercially available HEA (96%, Aldrich) contains impurities
such as acrylic acid, ethylene glycol, and ethyleneglycol diacrylate (EGDA)
Table 2. Pharmacokinetic parameters for 1% cross-linked RBCMs calculated from blood draws taken out to 5 d postinjection
A, mg∕mL B, mg∕mL α, h−1 β, h−1 αt1∕2, h βt1∕2, h VC, mL AUC, mg  h∕mL CLT , mL∕h Vdβ , mL
0.190 0.0482 0.241 0.00768 2.876 90.235 2.934 7.067 0.0990 12.894
























and was purified prior to use according to the procedure set forth by Elif and
Ali (37). Briefly, HEAwas dissolved in water (25% by volume) and the solution
extracted 10 times with hexanes. Salt (200 g of NaCl∕L) was added to
the aqueous phase, and the monomer was extracted by washing with ether
(4 times). The solution was dried with MgSO4 (3 wt %), and ether was re-
moved by rotary evaporator. The purified monomer was distilled under
vacuum prior to use. PEG 4000 diacrylate (DA) (Polysciences, Inc.), 2-carbox-
yethyl acrylate (Aldrich), fluorescein-o-acrylate (97%, Aldrich), 1-hydroxycy-
clohexyl phenyl ketone (99%, Aldrich), Dylight 680 maleimide (Thermo
Scientific), Fluorescein-o-acrylate (97%, Aldrich) and methacryloxyethyl
thiocarbamoyl rhodamine B (PolyFluor 570, Polysciences, Inc.) were used
as received. All other materials were used as received, unless otherwise
noted.
Modulus Testing. To measure the mechanical properties of the cross-linked
HEA hydrogels, we polymerized macroscopic coupons of the prepolymer mix-
tures described in Table S1 via UV light (λ ¼ 365 nm, power ¼ 20 mW∕cm2) in
a Teflon mold. The cross-linked hydrogels were removed from the mold,
weighed, and then placed in pH 7.4 PBS buffer for 24 h to fully hydrate.
The coupons were patted dry with paper towels and weighed again prior
to testing with an Instron 5556 Universal Testing Machine (Instron) with a
strain rate of 5 mm∕min.
Particle Fabrication. For the PRINT technique (9, 18), master templates were
prepared via traditional photolithography to have ordered arrays of raised
discs with low aspect ratios, mimicking the shape of RBCs. A photocurable
perfluoropolyether (Fluorocur, Liquidia Technologies) was drop cast onto a
master template, and a flexible plastic sheet was applied to the top of
the resin to act as a supportive backing for the mold that resulted from
photocuring of the resin and subsequent removal from the master template.
The master templates and molds used in this study had discoid features with
2- and 3-μm diameters and heights of 0.6 and 0.9 μm, respectively, and
produced particles with 5- to 6-μm diameters due to swelling of the particle
hydrogel material. For the fabrication of the particles, the prepolymer
mixture was spread onto a mold that was chilled to 2–5 °C on a custom-built
laminator platform. The reduced temperature prevented evaporation of the
prepolymer solution prior to photocuring. A poly(ethylene terepthalate)
(PET) sheet was laminated to the top of the mold and prepolymer solution,
wetting the total mold area. The sheet was peeled away at the nip point of
the laminator, leaving the wells of the mold filled while wicking away
excess solution. The filled mold was immediately transferred into a chilled
(2–5 °C), nitrogen purged UV oven and cured with UV light (λ ¼ 365 nm,
power ¼ 20 mW∕cm2). After curing, the filled mold was placed face down
on a thin film of 0.1% 2;000 g∕mol poly(vinyl alcohol) (PVOH, Acros) in water
on top of another PET sheet. This assembly was placed in a −80 °C cooler,
allowing the water to freeze and adhere to the particles. After freezing,
the mold was peeled away from the particles trapped in the ice layer, and
the ice was allowed to melt. RBCMs and water were collected, then washed
and concentrated via tangential flow filtration with a MicroKros hollow fiber
filter (500 kDa, Spectrum Laboratories, Inc.) to remove any sol fraction from
solution. Particles were then suspended in 0.1% 2;000 g∕mol PVOH in PBS,
pH 7.4 for subsequent experiments.
Particle Characterization. These methods (confocal microscopy, cell viability,
cell uptake, and zeta potential) are described in SI Text, Figs. S1 and S2,
and Table S2.
Microfluidics. Microfluidic devices were fabricated from silicone (Sylgard 184,
Dow Corning) sealed to glass after treatment with oxygen plasma, with flow
driven by a syringe pump at a fixed rate (0.06 μL∕min). Dilute solutions of 1%
cross-linked RBCMs (1–5 μg∕mL in PBS with 0.1% PVOH) were pumped
through the channel and observed with a fluorescence microscope (Nikon
TE2000). Videos were taken with a with a Photometrics Cascade II∶512 cam-
era. Particle stretching was analyzed with ImageJ software.
Intravital Microscopy. Intravital microscopy experiments were performed
using an IV 100 laser scanning microscope (Olympus) on female BALB/c mice
of 22- to 26-g body weight (Harlan Sprague Dawley). Hair was removed from
the ear and a tail vein catheter was applied. The mice were anesthetized with
isofluorane and placed onto a heated stage (37 °C) in a prone position, with
an ear immobilized by taping to an aluminum block. Vasculature was located
by injection with a solution of 20 mg∕mL rhodamine B labeled 70-kDa dex-
tran (Invitrogen) in PBS and visualized by excitation with a 568-nm laser. A
suspension of RBCMs, 33 mg particles∕kg mouse weight via a 3.5 mg∕mL
solution of RBCMs in PBS with 0.1% PVOH, was then injected and visualized
using a 633-nm laser. Controls were injected with the dextran solution
followed by 200 μL of PBS with 0.1% poly(vinyl alcohol). Imaging scans pro-
ceeded for 2 h, with an image taken every 2 s. For analysis of the circulation
persistence of the particles, the image files from each scan were exported to
imageJ. For ease of analysis, we followed the example of Tong et al. (38) and
stacked the images in groups of 10. We analyzed the region of interest
containing vasculature for fluorescent signal in each scan and corrected
for variation in laser intensity or autofluorescence by background correcting
each image with the signal from a region of the scan that was free of vas-
Fig. 4. Biodistribution of RBCMs. (A) Distribution of
RBCMs into various tissues 2 h postdosing by percent
recovered fluorescence normalized for tissue weight.
Error bars represent one standard deviation, with
n ¼ 3 for each case. (B) Lung tissue from a mouse dosed
with 10% cross-linked RBCMs. Particles are shown in
red, with cell nuclei in purple, and cytoskeleton (F-actin)
stained green. (C) Lung tissue from a mouse dosed with
1% cross-linked RBCMs, with tissue stained as in B. Very
few RBCMs were in this tissue compared to mice dosed
with more rigid particles, consistent with the tissue dis-
tribution data. Scale bars are 50 μm.
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culature. For comparison, we normalized each scan to the maximum intensity
slice for that scan, providing curves that measured the clearance of particles
from the peripheral vasculature over time as a percentage of the maximum
signal. Further details are outlined in SI Text.
Controls and dosed mice were sacrificed 2 h after injections, and blood
and tissues were harvested for imaging. Harvested tissues including liver,
lung, spleen, kidneys, heart, and intestines were weighed, then imaged using
an IVIS Kinetic fluorescence imaging system (Caliper Life Sciences) with exci-
tation at 675 nm and emission measured at 720 nm. Blood was harvested via
cardiac puncture and pipetted in 100-μL aliquots to black 96-well plates for
analysis on the imager. The fluorescent signal for each tissue sample was
background corrected by subtracting the signal from control tissues. Biodis-
tribution profiles for the RBCMs at 2 h postdose were determined by percent
of recovered fluorescence in the above tissues (Fig. 4). Fluorescent signal in
the blood was calculated by measuring the fluorescent signal from several
aliquots of blood and extrapolating to account for the total blood volume
in the mice (approximately 1.7 mL∕20 g of body weight) (39).
Biodistribution. Harvested blood was analyzed for fluorescent signal with an
IVIS Kinetic imager with excitation at 675 nm and emission measured at
720 nm, and concentrations were calculated with a standard curve. Harvested
tissues were analyzed as above, with biodistribution profiles presented as a
percent of the recovered fluorescence per gram of tissue weight.
Blood-Draw Experiments. For evaluation of longer time points, particles were
injected as in the previously described study, with mice sacrificed at the in-
dicated time points by cardiac puncture. Fluorescent signal from harvested
blood was measured as above, with concentrations determined from a stan-
dard curve resulting from serial dilutions of particles in mouse blood (Fig. S2).
Hisology. Details of the procedure for staining and imaging the harvested
tissues are found in SI Text.
Pharmacokinetic Analysis. Further details on the pharmacokinetic analysis
carried out for the RBCMs can be found in SI Text.
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